CRSP Quote, Financials, Valuation and Earnings

Intellia Therapeutics has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of -687.61%. CRISPR Therapeutics AG's return on equity of -18.65% beat Intellia Therapeutics's return on equity of -56.9%.

CRISPR Therapeutics AG has a consensus price target of $81.80, signalling upside risk potential of 48.34%. On the other hand Intellia Therapeutics has an analysts' consensus of $37.11 which suggests that it could grow by 210.29%. Given that Intellia Therapeutics has higher upside potential than CRISPR Therapeutics AG, analysts believe Intellia Therapeutics is more attractive than CRISPR Therapeutics AG.

CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison Intellia Therapeutics has a beta of 2.211, suggesting its more volatile than the S&P 500 by 121.143%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intellia Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Intellia Therapeutics pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $35M, which are larger than Intellia Therapeutics quarterly revenues of $16.6M. CRISPR Therapeutics AG's net income of -$136M is lower than Intellia Therapeutics's net income of -$114.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Intellia Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 26.47x for Intellia Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 26.48%. CRISPR Therapeutics AG's return on equity of -18.65% beat Novartis AG's return on equity of 30.96%.

CRISPR Therapeutics AG has a consensus price target of $81.80, signalling upside risk potential of 48.34%. On the other hand Novartis AG has an analysts' consensus of $113.44 which suggests that it could fall by -4.16%. Given that CRISPR Therapeutics AG has higher upside potential than Novartis AG, analysts believe CRISPR Therapeutics AG is more attractive than Novartis AG.

CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison Novartis AG has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.101%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novartis AG offers a yield of 3.37% to investors and pays a quarterly dividend of $3.99 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Novartis AG quarterly revenues of $13.6B. CRISPR Therapeutics AG's net income of -$136M is lower than Novartis AG's net income of $3.6B. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Novartis AG's PE ratio is 18.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 4.48x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

BeOne Medicines has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 0.11%. CRISPR Therapeutics AG's return on equity of -18.65% beat BeOne Medicines's return on equity of -11.54%.

CRISPR Therapeutics AG has a consensus price target of $81.80, signalling upside risk potential of 48.34%. On the other hand BeOne Medicines has an analysts' consensus of $332.60 which suggests that it could grow by 19.14%. Given that CRISPR Therapeutics AG has higher upside potential than BeOne Medicines, analysts believe CRISPR Therapeutics AG is more attractive than BeOne Medicines.

CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison BeOne Medicines has a beta of 0.282, suggesting its less volatile than the S&P 500 by 71.823%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BeOne Medicines offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. BeOne Medicines pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than BeOne Medicines quarterly revenues of $1.1B. CRISPR Therapeutics AG's net income of -$136M is lower than BeOne Medicines's net income of $1.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while BeOne Medicines's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 7.17x for BeOne Medicines. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of -106.6% compared to CRISPR Therapeutics AG's net margin of 23.33%. CRISPR Therapeutics AG's return on equity of -18.65% beat Vertex Pharmaceuticals's return on equity of -6.04%.

CRISPR Therapeutics AG has a consensus price target of $81.80, signalling upside risk potential of 48.34%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $500.30 which suggests that it could grow by 6.55%. Given that CRISPR Therapeutics AG has higher upside potential than Vertex Pharmaceuticals, analysts believe CRISPR Therapeutics AG is more attractive than Vertex Pharmaceuticals.

CRISPR Therapeutics AG has a beta of 1.822, which suggesting that the stock is 82.156% more volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.410, suggesting its less volatile than the S&P 500 by 59.044%.

CRISPR Therapeutics AG has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CRISPR Therapeutics AG pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

CRISPR Therapeutics AG quarterly revenues are $35M, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. CRISPR Therapeutics AG's net income of -$136M is lower than Vertex Pharmaceuticals's net income of $646.3M. Notably, CRISPR Therapeutics AG's price-to-earnings ratio is -- while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CRISPR Therapeutics AG is -- versus 10.96x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.